Design and Synthesis of Tesirine, a Clinical Antibody–Drug Conjugate Pyrrolobenzodiazepine Dimer Payload-Reference-Cited by-同舟云学术

Design and Synthesis of Tesirine, a Clinical Antibody–Drug Conjugate Pyrrolobenzodiazepine Dimer Payload

Published:2016-06-08 Issue:11 Volume:7 Page:983-987
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Tiberghien Arnaud C.¹,Levy Jean-Noel¹,Masterson Luke A.¹,Patel Neki V.¹,Adams Lauren R.¹,Corbett Simon¹,Williams David G.¹,Hartley John A.¹,Howard Philip W.¹

Affiliation:

1. QMB Innovation Centre, Spirogen, 42 New Road, E1 2AX London, U.K.

Funder

AstraZeneca

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.6b00062

Reference33 articles.

1. Isolation and Characterization of Anthramycin, a New Antitumor Antibiotic

2. ‘Refuin’ : a Non-cytotoxic Carcinostatic Compound proliferated by a Thermophilic Actinomycete

3. The development of pyrrolobenzodiazepines as antitumour agents

4. SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

5. Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy

Cited by 124 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural-source payloads used in the conjugated drugs architecture for cancer therapy: Recent advances and future directions;Pharmacological Research;2024-09

2. Targeted Drug Conjugates in Cancer Therapy: Challenges and Opportunities;Pharmaceutical Science Advances;2024-08

3. Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein;Cancer Research Communications;2024-06-12

4. Antibody–Drug Conjugates in the Pipeline for Treatment of Melanoma: Target and Pharmacokinetic Considerations;Drugs in R&D;2024-06

5. A new step toward non-genotoxic conditioning prior to hematopoietic stem cell transplantation;Molecular Therapy;2024-06